Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, NET), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2025 - 2030

Somatostatin Analogs Market Size & Trends

The global somatostatin analogs market size was estimated at USD 5.22 billion in 2024 and is projected to grow at a CAGR of 13.3% from 2025 to 2030. The increasing prevalence of Neuroendocrine Tumors (NETs), acromegaly, Cushing syndrome, excessive hormone production, and other related diseases is expected to accelerate the growth.

Some NETs produce excess hormones, causing symptoms. Somatostatin analogs help control hormone levels, relieve symptoms, slow cancer growth, and may reduce tumor size.

According to a report in 2023, the global incidence of Cushing's syndrome is estimated at 1.8 to 4.5 cases per million people annually, while its overall prevalence is estimated to range from 57 to 79 cases per million individuals, considering all causes. It is more prevalent in females. Somatostatin analogs, especially pasireotide, can help manage Cushing's syndrome by decreasing the secretion of Adrenocorticotropic Hormone (ACTH) and cortisol.

Acromegaly is a chronic endocrine disorder that results from excessive growth hormone production, typically due to a pituitary adenoma. In 2023, acromegaly affected approximately 4,600 individuals per million globally, with around 116.9 new cases diagnosed per million each year, a number that continues to rise. The condition is typically identified around age 40 in men and 45 in women, often emerging in the third decade of life. The increasing incidence of acromegaly has driven the reliance and expansion of the somatostatin analogs industry.

Rising R&D initiatives and the launch of novel drug therapies are some factors driving the growth of the somatostatin analogs market. Favorable government insurance policies and schemes for patients with rare diseases contribute to the overall market growth. For instance, multiple government healthcare organizations in the U.S. and Europe, such as the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS), offer subsidized medicines for rare diseases.

Type Insights

Octreotide dominated the somatostatin analogs market, with a revenue share of 36.3% in 2024. This growth is attributable to its various therapeutic applications, such as severe diarrhea, acromegaly, carcinoid tumors, and vasoactive intestinal peptide tumors. According to WHO, diarrheal disease was the third leading cause of death in children aged 1-59 months, claiming around 443,832 lives under age 5 and causing an additional 50,851 deaths among children aged 5-9. Despite being preventable and treatable, it remains widespread, with 1.7 billion childhood cases annually.

The pasireotide segment is expected to grow at the fastest CAGR of 14.8% over the forecast period. Pasireotide injection treats Cushing's disease and acromegaly in adults who cannot undergo or have not responded to surgery. Pasireotide is approved by the U.S. Food and Drug Administration and European Medicines Agency for adults with Cushing's disease who have recurrent hypercortisolism post-surgery or cannot undergo surgery. A twice-daily dose of 600-1,200 μg normalizes cortisol levels in up to 28% of patients within 3 months while improving blood pressure, weight, lipid levels, and quality of life.

Application Insights

The NET segment dominated the somatostatin analogs market with the largest revenue share in 2024, owing to its use in treating the inhibited release of hormones produced by these tumors. In Brazil, out of 15,859 identified cases in 2024, 53.4% were reported in men and 63.3% of individuals were under the age of 65. Small cell carcinoma was the most common type, with 46.7% of cases. These cases were concentrated in high-complexity centers in Southeast Brazil, with treatment mainly involving surgery and chemotherapy. 

The acromegaly segment is expected to grow significantly over the forecast period. The growing awareness of acromegaly, combined with the availability of effective treatment options, is a key driver of this segment. Acromegaly Awareness Day is held every year on November 1st to raise awareness about this rare endocrine disorder and support those affected. Such initiatives promote early diagnosis and access to effective treatment and medications.

End-use Insights

Hospitals led the somatostatin analogs market, accounting for the largest revenue share in 2024. They are used to control hormone-related symptoms in NETs and endocrine disorders, prevent post-surgical complications such as pancreatic fistulas, and manage bleeding in liver conditions.

The clinics segment is expected to grow at the fastest CAGR of 14.4% over the forecast period. Multidisciplinary reference clinics for NETs and endocrine disorders bring together oncology, endocrinology, radiology, and nursing experts to provide integrated care. These clinics improve outcomes by reducing diagnosis delays, offering diverse treatments, and ensuring continuous support.  

Regional Insights

The North America somatostatin analogs market dominated the global market, with the largest revenue share of 42.3% in 2024. The high prevalence of NETs and acromegaly is predicted to be the preliminary driver responsible for regional growth. In addition, the presence of key players in the region, such as Novo Nordisk A/S and Pfizer Inc. and increasing awareness are also expected to drive the market growth. Diabetes is one of the major disorders linked to endocrine dysfunction. In 2021, approximately 38.4 million Americans, or 11.6% of the population, were living with diabetes. Of these, around 2 million individuals had type 1 diabetes, including approximately 304,000 children and adolescents, according to the American Diabetes Association , which drives segment demand.

U.S. Somatostatin Analogs Market Trends

The U.S. somatostatin analogs market dominated the region with the largest revenue share in 2024. NETs are a significant factor driving the somatostatin analogs industry. Each year, approximately 12,000 people in the U.S. are diagnosed with NETs. Furthermore, somatostatin analogs are commonly used as postsurgical therapy, especially in cases of acromegaly, and to prevent pancreatic fistulas following surgery. The University of Pennsylvania Health System, in conjunction with the Perelman School of Medicine in Philadelphia, performs approximately 180 major pancreatic surgeries annually in the U.S.

Europe Somatostatin Analogs Market Trends

Europe's somatostatin analogs market held a substantial share in 2024. The rising number of NET patients is a key factor driving regional market growth. Disorders related to excessive hormone production, such as thyroid conditions, are commonly reported across Europe. Thyroid nodules are the most prevalent endocrine disorder and are being diagnosed at an increasing frequency. In 2019, Germany reported 5,074,512 individuals underwent at least one thyroid diagnostic procedure, and 1,435,780 individuals received at least one form of thyroid treatment.

Asia Pacific Somatostatin Analogs Market Trends

Asia Pacific somatostatin analogs market is expected to grow at the fastest CAGR of 14.7% over the forecast period. An increase in the rate of NET diagnosis in countries such as South Korea, Japan, and India, coupled with rising per capita income, is one of the high-impact drivers for the market. Furthermore, growing investments by pharmaceutical companies are projected to present remunerative growth opportunities in the near future.

The China somatostatin analogs market dominated the Asia Pacific market with the largest revenue share in 2024. The country's high number of pancreatic surgeries is a major factor driving the somatostatin analogs industry, as it prevents pancreatic fistulas. The Pancreatic Surgery Department at West China Hospital of Sichuan University is recognized as a key discipline by the Ministry of Health. Each year, the department handles approximately 42,000 outpatient visits for pancreatic surgery and performs around 3,700 surgical procedures.

Key Somatostatin Analogs Company Insights

Some of the major companies in the somatostatin analogs industry are Novo Nordisk A/S, Pfizer Inc., Eli Lilly and Company, and Medical Device Business Services, Inc. These companies are focused on implementing strategies such as the development of new formulations, partnerships and distribution agreements, and regional expansion to increase their revenue shares.

• Novo Nordisk A/S provides products for diabetes care and hormone-related disorders. While primarily focused on insulin and GLP-1 therapies, the company also develops treatments such as somatostatin analogs for managing endocrine conditions such as acromegaly and neuroendocrine tumors.

• Pfizer Inc., a biopharmaceutical company, focuses on discovering, developing, and manufacturing innovative medicines and vaccines. Pfizer's portfolio spans various therapeutic areas, including oncology, immunology, cardiology, and endocrinology.

Recent Developments

• In May 2024, Cipla Limited and its subsidiary, Cipla USA Inc., received final approval from the U.S. FDA for their Abbreviated New Drug Application for Lanreotide Injection (60 mg, 90 mg, 120 mg). This AP-rated generic version of Somatuline Depot is indicated for treating acromegaly and gastroenteropancreatic NETs.

• In December 2023, Camurus AB submitted a New Drug Application (NDA) to the U.S. FDA for Oclaiz (CAM2029), a once-monthly subcutaneous octreotide depot for treating acromegaly.

Somatostatin Analogs Market Report Scope

Global Somatostatin Analogs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global somatostatin analogs market report based on type, application, end-use, and region:

• Type Outlook (Revenue, USD Million; 2018 - 2030)

  • Octreotide

  • Lanreotide

  • Pasireotide

  • Others

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • Acromegaly

  • NET

  • Others

• End-use Outlook (Revenue, USD Million; 2018 - 2030)

  • Hospitals

  • Clinics

  • Others

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Russia

  • Asia Pacific

    • India

    • China

    • South Korea

    • Hong Kong

    • Australia

    • Singapore

    • Japan

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • Kuwait

    • Saudi Arabia

    • South Africa

    • UAE